OpGen Announces Completion of the Intermountain Healthcare Retrospective MDRO Health Outcome Study
August 08 2016 - 11:26AM
OpGen, Inc. (NASDAQ:OPGN), an informatics and genomic analysis
company, announces the completion of its multi-drug resistant
organisms (MDRO) health outcomes study with Intermountain
Healthcare. It was a collaboration between Intermountain Healthcare
and Enterprise Analysis Corporation (EAC) in a retrospective study
to explore multi-drug resistant organisms and Clostridium difficile
trends throughout the Intermountain Healthcare System over an
8-year period (2008-2015). The study was requested and funded by
OpGen.
The objectives of the study included:
- Examine the antibiotic resistance burden within the
Intermountain Healthcare System and associated epidemiology;
- Establish the timeliness by which antibiotic resistance has
been identified in the microbiology laboratories using conventional
culture methods;
- Explore the relationship between microbiology results
turnaround time and effective antibiotic use;
- Estimate the possible benefits of a shorter turnaround time on
duration of empiric, and time to effective, antibiotic therapy in
patients with MDRO infections;
- Project improvements in medical outcomes;
- Assess the possible beneficial impact of such improved
diagnostics on healthcare costs.
“This comprehensive retrospective study, conducted by
Intermountain Healthcare, should provide significant insights into
how healthcare systems can reduce infections and improve health
outcomes,” said Rob Lilley, Chief Commercial Officer at OpGen.
Given the complexity of the targets in this study – Gram
negative organisms such as E. coli, Klebsiella, Acinetobacter,
Enterobacter, Pseudomonas that were resistant to three or more
classes of antibiotics, and additional pathogens such as VRE, MRSA,
and C. difficile – Intermountain Healthcare narrowed down their
sample patient population from 900,000 to a total of 12,750
inpatient MDRO encounters, after applying the study criteria. EAC
conducted a statistical analysis of the data for this study.
“We are proud to have supported a study of this magnitude and to
work with one of the nation's most respected integrated health
networks,” said Evan Jones, Chairman and CEO of OpGen. “The next
phase of the collaboration will focus on the use of OpGen’s
technologies to help guide clinical decisions with a goal of
improving patient outcomes and reducing costs associated with
drug-resistant pathogen and C. difficile infections.”
About OpGenOpGen is harnessing the power of
informatics and genomic analysis to provide complete solutions for
patient, hospital and network-wide infection prevention and
treatment. For more information, visit www.opgen.com.
About Intermountain Healthcare Intermountain
Healthcare is a Utah-based, not-for-profit system of 22 hospitals,
185 clinics, a Medical Group with over 1,400 employed physicians
and advanced practice clinicians, a health plans division called
SelectHealth, and other health services. Helping people live the
healthiest lives possible, Intermountain is widely recognized as a
leader in transforming healthcare through high quality and
sustainable costs. For more information about Intermountain,
visit intermountainhealthcare.org.
Forward-Looking Statements This press release
includes statements relating to the company's support of the
Intermountain Healthcare retrospective study and the next steps
involving the use of the company’s Acuitas MDRO, Acuitas Lighthouse
and QuickFISH products and services to help guide clinical
decisions regarding MDROs These statements and other statements
regarding our future plans and goals constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control, and which
may cause results to differ materially from expectations. Factors
that could cause our results to differ materially from those
described include, but are not limited to, the rate of adoption of
our products and services by hospitals and other healthcare
providers, the success of our commercialization efforts, the effect
on our business of existing and new regulatory requirements, and
other economic and competitive factors. For a discussion of the
most significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission (SEC). You are cautioned not to place undue
reliance on these forward-looking statements, which are based on
our expectations as of the date of this press release and speak
only as of the date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Contacts:
OpGenMichael FarmerDirector, Marketing(240)
813-1284
mfarmer@opgen.comInvestorRelations@opgen.com
Investor RelationsLHAKim Sutton Golodetz(212)
838-3777kgolodetz@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
OpGen Media MacDougall Biomedical
Communications Cammy Duong781-591-3443cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024